Rezolute
Dr. Hood, a long-standing member of the patient advocacy group Congenital Hyperinsulinism International (CHI), joins the Rezolute team as Director of Scientific and Patient Affairs. She has served in various scientific and leadership capacities such as the President of the Board of Directors and Principal Investigator for the HI Global Registry. Dr. Hood’s breadth and depth of experience within the HI community will be of tremendous value in the execution of the RZ358 development program, and guide us in a direction that captures the needs of the patients and fosters collaborative relationships within the scientific community.
This person is not in any offices
Rezolute
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.